Literature DB >> 1855352

The intellectual health of clinical drug evaluation.

L B Sheiner1.   

Abstract

Mesh：

Year:  1991        PMID： 1855352     DOI： 10.1038/clpt.1991.97

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  22 in total

1.  Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.

Authors:  R L Williams; W Adams; M L Chen; D Hare; A Hussain; L Lesko; R Patnaik; V Shah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

Review 2.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 3.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

4.  Is bigger better? An argument for very low starting doses.

Authors:  James P McCormack; G Michael Allan; Adil S Virani
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 5.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

Review 6.  Population pharmacokinetics/pharmacodynamics of anesthetics.

Authors:  Erik Olofsen; Albert Dahan
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 7.  Precision medicine in cardiology.

Authors:  Elliott M Antman; Joseph Loscalzo
Journal:  Nat Rev Cardiol       Date:  2016-06-30       Impact factor: 32.419

Review 8.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 9.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 10.  What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

Authors:  V Ozdemir; N H Shear; W Kalow
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.